12-Nov-2024 3:05 PM CST - Business Wire MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position MEI Pharma, Inc. (Nasdaq: MEIP) (the Company) today reported results for its quarter ended September 30, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. In the review, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders.
19-Sep-2024 3:01 PM CST - Business Wire MEI Pharma Reports Fiscal Year End 2024 Cash Position MEI Pharma, Inc. (Nasdaq: MEIP) (the Company) today reported results for its fiscal year ended June 30, 2024. Previously on July 22, 2024, the Company announced the commencement of an evaluation of strategic alternatives with the goal of maximizing the value of its assets for its stockholders. Subsequent to that date, the Company announced the engagement of Oppenheimer & Co., Inc. to serve as the Companys exclusive financial adviser to assist in the review and
12-Nov-2024 3:05 PM CST - Business Wire MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position MEI Pharma, Inc. (Nasdaq: MEIP) (the Company) today reported results for its quarter ended September 30, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. In the review, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders.
19-Sep-2024 3:01 PM CST - Business Wire MEI Pharma Reports Fiscal Year End 2024 Cash Position MEI Pharma, Inc. (Nasdaq: MEIP) (the Company) today reported results for its fiscal year ended June 30, 2024. Previously on July 22, 2024, the Company announced the commencement of an evaluation of strategic alternatives with the goal of maximizing the value of its assets for its stockholders. Subsequent to that date, the Company announced the engagement of Oppenheimer & Co., Inc. to serve as the Companys exclusive financial adviser to assist in the review and
